22561), CD, I
supplemented, VBN, I
with, IN, I
20%, CD, I
FBS, NNP, I
(PAA, NNP, I
Laboratories), NNP, I
GlutaMAX, NNP, I
penicillin, NN, I
(100U/mL), NN, I
and, CC, I
streptomycin, NN, I
(100, NNP, I
mg/mL), NN, I
(all, NN, I
from, IN, I
Life, NNP, I
Technologies), NNP, I
at, IN, I
37C, CD, I
and, CC, I
5%, CD, I
CO2., NN, IAbout, IN, I
85%, CD, I
of, IN, I
the, DT, I
cell, NN, I
population, NN, I
in, IN, I
this, DT, I
bone, NN, I
tissue, NN, I
are, VBP, I
osteocytes, NNS, I
and, CC, I
the, DT, I
remainder, NN, I
are, VBP, I
osteoblasts, VBZ, I
bone, NN, N
marrow, NN, N
etc., NN, IA, DT, I
core, NN, I
set, NN, I
of, IN, I
differentially, RB, I
methylated, VBN, I
regions, NNS, I
in, IN, I
APL, NNP, I
was, VBD, I
identified., JJ, IA, DT, I
detailed, JJ, I
characterization, NN, I
of, IN, I
the, DT, I
mRNA-, NN, I
and, CC, I
microRNA, NN, I
transcriptomes, NNS, I
during, IN, I
adipocyte, JJ, I
differentiation, NN, I
also, RB, I
showed, VBD, I
that, IN, I
the, DT, I
iMSC#3, NN, I
recapitulates, VBZ, I
this, DT, I
process, NN, I
at, IN, I
the, DT, I
molecular, JJ, I
level., NN, IAfter, IN, I
informed, VBN, I
consent, NN, I
bone, NN, N
marrow, NN, N
specimens, VBZ, I
packed, VBN, I
with, IN, I
leukemic, JJ, I
blasts, NNS, I
were, VBD, I
obtained, VBN, I
in, IN, I
each, DT, I
patient., NN, IAge, NNP, I
at, IN, I
diagnosis, NN, I
Sanz, NNP, I
score, NN, I
and, CC, I
Flt3-mutation, NN, I
status, NN, I
characterized, VBN, I
methylation, NN, I
subtypes., NN, IAPL, NNP, I
patients, NNS, I
showed, VBD, I
increased, JJ, I
genome-wide, JJ, I
DNA, NNP, I
methylation, NN, I
with, IN, I
higher, JJR, I
variability, NN, I
than, IN, I
healthy, JJ, I
CD34+, NNP, I
cells, NNS, I
promyelocytes, NNS, I
and, CC, I
remission, NN, I
bone, NN, N
marrow, NN, N
., ., IA, DT, I
total, NN, I
of, IN, I
231, CD, I
pediatric, JJ, I
patients, NNS, I
with, IN, I
B-ALL, NNP, I
were, VBD, I
utilized, VBN, I
from, IN, I
the, DT, I
California, NNP, I
Childhood, NNP, I
Cancer, NNP, I
Study., NNP, IATRA, NNP, I
treatment, NN, I
of, IN, I
APL, NNP, I
blasts, NNS, I
did, VBD, I
also, RB, I
not, RB, I
result, VB, I
in, IN, I
DNA, NNP, I
methylation, NN, I
changes., NN, IBisulphite, NNP, I
converted, VBD, I
DNA, NNP, I
from, IN, I
all, DT, I
samples, NNS, I
were, VBD, I
hybridised, VBN, I
to, TO, I
the, DT, I
Illumina, NNP, I
Infinium, NNP, I
450, CD, I
Human, NNP, I
Methylation, NNP, I
arrays, NNS, I
and, CC, I
for, IN, I
each, DT, I
analysis, NN, I
the, DT, I
drug, NN, I
treated, VBD, I
sample, NN, I
was, VBD, I
compared, VBN, I
to, TO, I
the, DT, I
corresponding, JJ, I
PBS, NNP, I
control, NN, I
sample., NN, Ibone, NN, N
marrow, NN, N
biopsy, NN, I
AraC, NNP, Ibone, NN, N
marrow, NN, N
biopsy, NN, I
DAC, NNP, Ibone, NN, N
marrow, NN, N
biopsy, NN, I
mock, NN, Ibone, NN, N
marrow, NN, N
cells, NNS, I
collected, VBN, I
from, IN, I
healthy, JJ, I
donors, NNS, I
were, VBD, I
sorted, VBN, I
and, CC, I
DNA, NNP, I
extracted, VBD, I
at, IN, I
Washington, NNP, I
University, NNP, I
in, IN, I
St., NNP, I
Louis, NNP, I
microarrays, NNS, I
were, VBD, I
then, RB, I
run, VBN, I
at, IN, I
USC, NNP, Ibone, NN, N
marrow, NN, N
-derived, VBD, I
mesenchymal, JJ, I
stroma, NN, I
cells, NNS, I
(MSCs), VBP, I
have, VBP, I
many, JJ, I
of, IN, I
the, DT, I
properties, NNS, I
of, IN, I
multipotent, JJ, I
stem, NN, I
cells, NNS, I
and, CC, I
can, MD, I
be, VB, I
differentiated, VBN, I
towards, JJ, I
osteoblasts, NNS, I
in, IN, I
vitro, NN, I
making, VBG, I
these, DT, I
cells, NNS, I
a, DT, I
convenient, JJ, I
tool, NN, I
for, IN, I
investigation, NN, I
of, IN, I
osteogenesis., NN, Ibone, NN, N
marrow, NN, N
-derived, VBD, I
MSC, NNP, I
(iP-MSC), NN, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
00_751, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
01_1808, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
02_1505, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
02_1522, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
02_1550, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
02_723, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
03_106, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
03_1310, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
03_1380, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
04_126, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
04_6, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
05_1464, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
05_170, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
05_579, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
06_2096, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
06_518, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
06_758, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
07_1768, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
07_1962, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
07_2252, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
08_151, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
08_723, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
08_774, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
08_785, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
08_930, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
10_1420, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
10_1789, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
11_834, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
12_254, CD, Ibone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, I
leukemia, NN, Ibone, NN, N
marrow, RBS, N
MSC-derived, JJ, I
iPS, NN, I
cells, NNS, I
(iPSCs), VBP, Ibone, NN, N
marrow, NN, N
sample, NN, I
grown, VBN, I
in, IN, I
cultutre, NN, IBy, IN, I
sequencing, VBG, I
of, IN, I
immuno¬precipi¬tated, JJ, I
chromatin, NN, I
we, PRP, I
generated, VBD, I
high, JJ, I
resolution, NN, I
maps, NNS, I
of, IN, I
enrichment, NN, I
of, IN, I
five, CD, I
histone, NN, I
H3, NNP, I
modifications, NNS, I
associated, VBN, I
with, IN, I
different, JJ, I
functional, JJ, I
states, NNS, I
of, IN, I
chromatin, NN, I
and, CC, I
identified, VBD, I
differentiation-induced, JJ, I
epigenetic, JJ, I
changes., NN, IBy, IN, I
the, DT, I
same, JJ, I
approach, NN, I
several, JJ, I
thousand, CD, I
binding, VBG, I
sites, NNS, I
for, IN, I
the, DT, I
transcription, NN, I
factor, NN, I
RUNX2, NNP, I
was, VBD, I
mapped, VBN, I
to, TO, I
around, IN, I
1900, CD, I
target, NN, I
genes, NNS, I
in, IN, I
differentiated, JJ, I
osteoblasts., NN, Icell, NN, I
description:, VBZ, I
neuroblastoma, JJ, I
BE-C, NNP, I
is, VBZ, I
a, DT, I
clone, NN, I
of, IN, I
the, DT, I
SK-N-BE, NNP, I
neuroblastoma, NN, I
cell, NN, I
line, NN, I
(see, NNP, I
ATCC, NNP, I
CRL-2271), NNP, I
that, WDT, I
was, VBD, I
established, VBN, I
in, IN, I
November, NNP, I
of, IN, I
1972, CD, I
from, IN, I
a, DT, I
bone, NN, N
marrow, NN, N
biopsy, NN, I
taken, VBN, I
from, IN, I
a, DT, I
2-year-old, JJ, I
individual, NN, I
with, IN, I
disseminated, JJ, I
neuroblastoma, NN, I
after, IN, I
repeated, VBN, I
courses, NNS, I
of, IN, I
chemotherapy, NN, I
and, CC, I
radiotherapy., NN, ICells, NNP, I
able, JJ, I
to, TO, I
form, VB, I
bone, NN, I
through, IN, I
endochondral, JJ, I
ossification, NN, I
and, CC, I
attract, VB, I
bone, NN, N
marrow, NN, N
in, IN, I
an, DT, I
innovative, JJ, I
in, IN, I
vivo, JJ, I
model, NN, I
were, VBD, I
compared, VBN, I
to, TO, I
cells, NNS, I
lacking, VBG, I
these, DT, I
capacities., NNS, Icells, NNS, I
isolated, VBN, I
from, IN, I
healthy, JJ, I
bone, NN, N
marrow, NN, NCells, NNS, I
were, VBD, I
expanded, VBN, I
in, IN, I
standard, JJ, I
alpha-MEM, NN, I
supplemented, VBN, I
with, IN, I
pooled, JJ, I
human, JJ, I
platelet, NN, I
lysate, NN, I
fully, RB, I
replacing, VBG, I
fetal, JJ, I
bovine, NN, I
serum., NN, ICells, NNS, I
were, VBD, I
passaged, VBN, I
every, DT, I
5-6, JJ, I
days, NNS, I
enzymatically, RB, I
with, IN, I
dispase, NN, I
(1, NNP, I
g/ml, NN, I
Stemcell, NNP, I
Technologies)., NNP, Icell, NN, I
type:, VBZ, I
bone, NN, N
marrow, NN, N
mononuclear, VBP, I
cells, NNS, Icell, NN, I
type:, VBZ, I
normal, JJ, I
bone, NN, N
marrow, NN, N
progenitor, NN, I
cells, NNS, ICMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, Nc-myc, JJ, I
binding, NN, I
sites, NNS, I
were, VBD, I
associated, VBN, I
with, IN, I
low, JJ, I
methylation., NN, ICN-AML, JJ, I
blasts, NNS, I
isolated, VBD, I
from, IN, I
patient, JJ, I
bone, NN, N
marrow, NN, N
aspriation, NN, I
were, VBD, I
compared, VBN, I
to, TO, I
CD34+, NNP, I
cell, NN, I
population, NN, I
from, IN, I
healthy, JJ, I
donors, NNS, I
by, IN, I
DNA, NNP, I
methylation, NN, I
array, NN, I
and, CC, I
affymetrix, JJ, I
gene, NN, I
expression, NN, I
microarray., NN, IComparing, VBG, I
four, CD, I
commonly, RB, I
use, VBP, I
MSC, NNP, I
sources, NNS, I
(, (, I
bone, NN, N
marrow, NN, N
(BM), NNP, I
white, JJ, I
adipose, JJ, I
tissue, NN, I
(WAT), NNP, I
umbilical, JJ, I
cord, NN, I
(UC), NN, I
and, CC, I
skin), NN, I
we, PRP, I
found, VBD, I
only, RB, I
bone, JJ, N
marrow, JJ, N
(BM)-derived, JJ, I
MSCs, NNP, I
capable, NN, I
of, IN, I
endochondral, JJ, I
ossification, NN, I
and, CC, I
marrow, NN, I
attraction., NN, IDensity, NNP, I
centrifuged, VBD, I
bone, NN, N
marrow, NN, NDespite, IN, I
similarities, NNS, I
in, IN, I
morphology, NN, I
phenotype, NN, I
and, CC, I
in, IN, I
vitro, JJ, I
behavior, NN, I
Mesenchymal, NNP, I
Stromal, NNP, I
Cells, NNP, I
(MSC), NNP, I
form, VBP, I
various, JJ, I
tissue, NN, I
sources, NNS, I
show, VBP, I
striking, JJ, I
differences, NNS, I
in, IN, I
their, PRP$, I
in, IN, I
vivo, NN, I
potential, NN, I
to, TO, I
form, VB, I
bone, NN, I
cartilage, NN, I
and, CC, I
hematopoietic, JJ, I
support, NN, I
tissue., NN, IDespite, IN, I
similarities, NNS, I
in, IN, I
morphology, NN, I
phenotype, NN, I
and, CC, I
in, IN, I
vitro, JJ, I
behavior, NN, I
Mesenchymal, NNP, I
Stromal, NNP, I
Cells, NNP, I
(MSC), NNP, I
form, VBP, I
various, JJ, I
tissue, NN, I
sources, NNS, I
show, VBP, I
striking, JJ, I
differences, NNS, I
in, IN, I
their, PRP$, I
in, IN, I
vivo, NN, I
potential, NN, I
to, TO, I
form, VB, I
bone, NN, I
cartilage, NN, I
and, CC, I
hematopoietic, JJ, I
support, NN, I
tissue., NN, Idisease, NN, I
state:, NN, I
normal, JJ, I
bone, NN, N
marrow, NN, NDNA, NN, I
methylation, NN, I
(DNAm), NNP, I
profiles, NNS, I
of, IN, I
iPSCs, NN, I
maintained, VBD, I
some, DT, I
donor-specific, JJ, I
characteristics, NNS, I
whereas, IN, I
tissue-specific, JJ, I
senescence-associated, JJ, I
and, CC, I
age-related, JJ, I
DNAm, NNP, I
patterns, NNS, I
were, VBD, I
erased, VBN, I
during, IN, I
reprogramming., NN, IDNA, NN, I
was, VBD, I
extracted, VBN, I
from, IN, I
patient, JJ, I
bone, NN, N
marrow, NN, N
samples, NNS, I
and, CC, I
xenograft, NNP, I
bone, NN, N
marrow, NN, N
samples, NNS, I
using, VBG, I
Qiagen, NNP, I
Allprep, NNP, I
kit., NN, IDuring, IN, I
embryogenesis, NN, I
body, NN, I
growth, NN, I
and, CC, I
repair, VB, I
the, DT, I
bone, NN, I
substance, NN, I
is, VBZ, I
formed, VBN, I
by, IN, I
osteoblasts, NNS, I
which, WDT, I
are, VBP, I
derived, VBN, I
from, IN, I
mesenchymal, JJ, I
stem, NN, I
cells., NN, IEnrichment, NN, I
for, IN, I
CD34, NNP, I
and, CC, I
CD117, NNP, I
were, VBD, I
checked, VBN, I
via, IN, I
FACS, NNP, I
analysis., NN, IEstablished, VBN, I
iPSCs, NNS, I
were, VBD, I
maintained, VBN, I
on, IN, I
MEFs, NNP, I
in, IN, I
DMEM/F12, NNP, I
medium, NN, I
supplemented, VBD, I
with, IN, I
Glutamax, NNP, I
20%, CD, I
knockout, NN, I
serum, NN, I
replacer, NN, I
1%, CD, I
nonessential, JJ, I
amino, NN, I
acids, NNS, I
1x, CD, I
penicillin/streptomycin, JJ, I
1x, CD, I
L-glutamine, JJ, I
0.1, CD, I
mM, JJ, I
β-Mercaptoethanol, JJ, I
and, CC, I
50, CD, I
ng/ml, JJ, I
basic, JJ, I
fibroblast, NN, I
growth, NN, I
factor, NN, I
(Peprotech, NNP, I
Hamburg, NNP, I
Germany)., NNP, IExpression, NN, I
and, CC, I
methylation, NN, I
data, NNS, I
of, IN, I
purified, JJ, I
Pre-B, NNP, I
cells, NNS, I
in, IN, I
four, CD, I
developmental, JJ, I
stages, NNS, I
were, VBD, I
retrieved, VBN, I
from, IN, I
our, PRP$, I
previous, JJ, I
study, NN, I
(Lee, NNP, I
et, CC, I
al., JJ, I
Nucleic, NNP, I
Acids, NNP, I
Res, NNP, I
2012)., CD, IFor, IN, I
8, CD, I
indibiduals, NNS, I
DNAs, NNP, I
and, CC, I
RNAs, NNP, I
were, VBD, I
isolated, VBN, I
and, CC, I
the, DT, I
methylation, NN, I
and, CC, I
expression, NN, I
changes, NNS, I
during, IN, I
early, JJ, I
B-cell, NNP, I
development, NN, I
were, VBD, I
identified, VBN, I
using, VBG, I
the, DT, I
Illumina, NNP, I
HumanMethylation450, NNP, I
Beadchip, NNP, I
(Illumina), NNP, I
and, CC, I
GeneChip, NNP, I
Human, NNP, I
Gene, NNP, I
1.0, CD, I
ST, NNP, I
Array, NNP, I
(Affymetrix)., NN, IFor, IN, I
CD14, NNP, I
samples, NNS, I
enricment, NN, I
for, IN, I
CD14, NNP, I
was, VBD, I
controlled, VBN, I
by, IN, I
FACS, NNP, I
analysis., NN, IFor, IN, I
re-differentiation, NN, I
of, IN, I
iPSC, JJ, I
towards, NNS, I
iPS-MSCs, JJ, I
medium, NN, I
was, VBD, I
simply, RB, I
exchanged, VBN, I
for, IN, I
MSC, NNP, I
standard, JJ, I
medium, NN, I
supplemented, VBN, I
with, IN, I
10%, CD, I
human, JJ, I
platelet, NN, I
lysate, NN, I
(hPL), NN, I
for, IN, I
7, CD, I
days, NNS, I
and, CC, I
cells, NNS, I
were, VBD, I
then, RB, I
further, RB, I
passaged, VBN, I
in, IN, I
culture, NN, I
wells, NNS, I
coated, VBN, I
with, IN, I
0.1%, CD, I
gelatin, NN, I
(Sigma-Aldrich, JJ, I
St., NNP, I
Louis, NNP, I
CA, NNP, I
USA)., NNP, IFurthermore, RB, I
hypermethylation, NN, I
in, IN, I
iP-MSC, JJ, I
versus, NN, I
ESC, NNP, I
was, VBD, I
particularly, RB, I
enriched, VBN, I
in, IN, I
developmental, JJ, I
genes, NNS, I
as, RB, I
well, RB, I
as, IN, I
shore, NN, I
regions, NNS, I
next, IN, I
to, TO, I
CpG, NNP, I
islands, NNS, I
indicating, VBG, I
that, IN, I
these, DT, I
differences, NNS, I
are, VBP, I
not, RB, I
due, JJ, I
to, TO, I
tissue-specific, JJ, I
memory, NN, I
or, CC, I
random, NN, I
de, IN, I
novo, FW, I
methylation., NN, IFurthermore, RB, I
iMSC#3, NN, I
showed, VBD, I
no, DT, I
major, JJ, I
differences, NNS, I
from, IN, I
hMSCs, NN, I
regarding, VBG, I
surface, NN, I
marker, NN, I
expression., NN, IFurther, RB, I
we, PRP, I
identified, VBD, I
GTF2I, NNP, I
and, CC, I
TEAD2, NNP, I
as, IN, I
regulators, NNS, I
of, IN, I
differentiation, NN, I
by, IN, I
computational, JJ, I
prediction, NN, I
of, IN, I
over-represented, JJ, I
transcription, NN, I
factor, NN, I
motifs, NNS, I
in, IN, I
regions, NNS, I
with, IN, I
differential, JJ, I
histone, NN, I
modification, NN, I
enrichment., NN, IGenome, NNP, I
wide, JJ, I
DNA, NNP, I
methylation, NN, I
profiling, NN, I
of, IN, I
leukemia, JJ, I
stem, NN, I
blast, NN, I
cells, NNS, I
obtained, VBN, I
from, IN, I
15, CD, I
AML, NNP, I
patients, NNS, I
and, CC, I
of, IN, I
normal, JJ, I
hematopoietic, JJ, I
stem/progenitor, NN, I
cells, NNS, I
from, IN, I
5, CD, I
normal, JJ, I
bone, NN, N
marrow, NN, N
., ., Igenomic, JJ, I
DNA, NN, I
from, IN, I
bone, NN, N
marrow, NN, N
CD34+, NNP, I
cells, NNS, I
5729917060_RO3CO2, CD, Igenomic, JJ, I
DNA, NN, I
from, IN, I
bone, NN, N
marrow, NN, N
CD34+, NNP, I
cells, NNS, I
5729917060_RO4CO2, CD, Igenomic, JJ, I
DNA, NN, I
from, IN, I
bone, NN, N
marrow, NN, N
CD34+, NNP, I
cells, NNS, I
5729917060_RO5CO2, CD, Igenomic, JJ, I
DNA, NN, I
from, IN, I
bone, NN, N
marrow, NN, N
CD34+, NNP, I
cells, NNS, I
5729917060_RO6CO2, CD, Igenomic, JJ, I
DNA, NN, I
from, IN, I
bone, NN, N
marrow, NN, N
CD34+, NNP, I
cells, NNS, I
8359018137_RO1CO1, CD, Igenomic, JJ, I
DNA, NN, I
from, IN, I
bone, NN, N
marrow, NN, N
CD34+, NNP, I
cells, NNS, I
8359018152_RO1CO1, CD, Igenomic, JJ, I
DNA, NN, I
from, IN, I
bone, NN, N
marrow, NN, N
CD34+, NNP, I
cells, NNS, I
8363800011_RO1CO1, CD, Igenomic, JJ, I
DNA, NN, I
from, IN, I
bone, NN, N
marrow, NN, N
CD34+, NNP, I
cells, NNS, I
8363800011_RO2CO1, CD, Igenomic, JJ, I
DNA, NN, I
from, IN, I
bone, NN, N
marrow, NN, N
CD34+, NNP, I
cells, NNS, I
8363800026_RO1CO1, CD, Igenomic, JJ, I
DNA, NN, I
from, IN, I
bone, NN, N
marrow, NN, N
CD34+, NNP, I
cells, NNS, I
8363800026_RO2CO1, CD, Igenomic, JJ, I
DNA, NN, I
from, IN, I
CMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2627, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
CMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2710, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
CMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2712, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
CMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2748, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
CMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2753, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
GMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2627, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
GMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2710, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
GMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2712, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
GMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2748, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
GMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2753, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
HSC, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2627, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
HSC, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2710, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
HSC, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2712, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
HSC, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2748, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
HSC, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2753, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
L-MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2627, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
L-MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2710, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
L-MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2712, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
L-MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2748, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
L-MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2753, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
MEP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2627, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
MEP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2710, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
MEP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2712, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
MEP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2748, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
MEP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2753, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2627, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2710, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2712, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2748, NNP, Igenomic, JJ, I
DNA, NN, I
from, IN, I
MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
ID2753, NNP, IGenomic, NNP, I
DNA, NNP, I
was, VBD, I
extracted, VBN, I
and, CC, I
purified, VBN, I
from, IN, I
AML, NNP, I
and, CC, I
normal, JJ, I
bone, NN, N
marrow, NN, N
samples, NNS, I
using, VBG, I
Epicentre, NNP, I
Kit, NNP, I
according, VBG, I
to, TO, I
standard, JJ, I
instructions, NNS, IGlobal, JJ, I
DNA-methylation, NNP, I
profiles, NNS, I
of, IN, I
the, DT, I
initial, JJ, I
MSC, NNP, I
MSC-derived, NNP, I
iPSC, JJ, I
(iP-MSC), NN, I
and, CC, I
embryonic, JJ, I
stem, NN, I
cells, NNS, I
(ESC), VBP, I
were, VBD, I
then, RB, I
compared, VBN, I
using, VBG, I
a, DT, I
high, JJ, I
density, NN, I
DNA-methylation, NNP, I
array, NN, I
covering, VBG, I
more, JJR, I
than, IN, I
450000, CD, I
CpG, NNP, I
sites., NN, IGMP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, NHowever, RB, I
a, DT, I
disadvantage, NN, I
of, IN, I
primary, JJ, I
hMSCs, NN, I
is, VBZ, I
the, DT, I
limited, JJ, I
in, IN, I
vitro, JJ, I
lifespan, NN, I
but, CC, I
this, DT, I
can, MD, I
be, VB, I
overcome, VBN, I
by, IN, I
introduction, NN, I
of, IN, I
the, DT, I
catalytic, JJ, I
subunit, NN, I
of, IN, I
human, JJ, I
telomerase, NN, I
reverse, NN, I
transcriptase, NN, I
(TERT)., NN, IHSC, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, NHuman, NNP, I
DNA, NNP, I
methylation, NN, I
Beadchip, NNP, I
v1.2, NN, I
was, VBD, I
used, VBN, I
to, TO, I
obtain, VB, I
DNA, NNP, I
methylation, NN, I
profiles, NNS, I
across, IN, I
approximately, RB, I
486000, CD, I
CpGs., NNP, IHuman, NNP, I
fetal, JJ, I
bone, NN, N
marrow, NN, N
was, VBD, I
obtained, VBN, I
and, CC, I
using, VBG, I
flow, JJ, I
cytometry, NN, I
antibodies, NNS, I
four, CD, I
populations, NNS, I
of, IN, I
B-cell, NNP, I
developmental, JJ, I
stages, NNS, I
including, VBG, I
stage, NN, I
1, CD, I
(S1;, NNP, I
predominantly, RB, I
multipotent, VBD, I
progenitors, NNS, I
before, IN, I
lineage, JJ, I
commitment, NN, I
and, CC, I
common, JJ, I
lymphoid, NN, I
progenitors), NN, I
stage, NN, I
II, NNP, I
(S2;, NNP, I
pre-B-I, JJ, I
cells), NN, I
stage, NN, I
3, CD, I
(S3;, JJ, I
pre-B-II, JJ, I
cells), NN, I
and, CC, I
stage, NN, I
4, CD, I
cells, NNS, I
(S4;, JJ, I
immature, NN, I
B, NNP, I
cells)., NN, IImmortalized, NNP, I
human, JJ, I
bone, NN, N
marrow, NN, N
-derived, VBD, I
mesenchymal, JJ, I
stromal, JJ, I
cell, NN, I
line, NN, I
DNA, NNP, I
methylation, NN, I
[iMSC#3, NNP, I
(Culture, NN, I
I)], NNP, IImmortalized, NNP, I
human, JJ, I
bone, NN, N
marrow, NN, N
-derived, VBD, I
mesenchymal, JJ, I
stromal, JJ, I
cell, NN, I
line, NN, I
DNA, NNP, I
methylation, NN, I
[iMSC#3, NNP, I
(Culture, NN, I
II)], NNP, IIn, IN, I
conclusion, NN, I
DNA, NNP, I
methylation, NN, I
profiles, NNS, I
of, IN, I
iP-MSC, JJ, I
clones, NNS, I
from, IN, I
the, DT, I
same, JJ, I
donor, NN, I
were, VBD, I
closely, RB, I
related, VBN, I
despite, IN, I
heterogeneity, NN, I
of, IN, I
MSC., NNP, IiMSC#3, NN, I
were, VBD, I
grown, VBN, I
under, IN, I
the, DT, I
same, JJ, I
condition, NN, I
as, IN, I
hMSCs, NN, I
but, CC, I
the, DT, I
medium, NN, I
was, VBD, I
supplemented, VBN, I
with, IN, I
10%, CD, I
FBS., NNS, IIn, IN, I
line, NN, I
myeloid, NN, I
cells, NNS, I
from, IN, I
pre-leukemic, JJ, I
PML-RARa, JJ, I
knock-in, JJ, I
mice, NN, I
did, VBD, I
not, RB, I
show, VB, I
altered, JJ, I
DNA, NNP, I
methylation, NN, I
and, CC, I
expression, NN, I
of, IN, I
PML-RARa, NNP, I
in, IN, I
hematopoietic, JJ, I
progenitor, NN, I
cells, NNS, I
prevented, VBN, I
differentiation, NN, I
without, IN, I
affecting, VBG, I
DNA, NNP, I
methylation., NN, IIn, IN, I
conclusion, NN, I
a, DT, I
human, JJ, I
bone, NN, N
marrow, NN, N
-derived, VBD, I
stromal, JJ, I
cell, NN, I
line, NN, I
was, VBD, I
developed, VBN, I
which, WDT, I
can, MD, I
be, VB, I
used, VBN, I
for, IN, I
basic, JJ, I
studies, NNS, I
of, IN, I
mesenchymal, JJ, I
cells, NNS, I
and, CC, I
to, TO, I
functionally, RB, I
study, VB, I
transgenes, NNS, I
that, WDT, I
might, MD, I
play, VB, I
a, DT, I
role, NN, I
in, IN, I
oncogenic, JJ, I
transformation., NN, IIn, IN, I
parallel, NN, I
we, PRP, I
have, VBP, I
isolated, VBN, I
RNA, NNP, I
from, IN, I
all, DT, I
sources, NNS, I
to, TO, I
analyze, VB, I
tissue, NN, I
source, NN, I
specific, JJ, I
gene, NN, I
expression, NN, I
profile., NN, IIn, IN, I
contrast, NN, I
induced, JJ, I
pluripotent, JJ, I
stem, NN, I
cells, NNS, I
(iPSCs), JJ, I
assimilate, VBP, I
towards, NNS, I
a, DT, I
ground-state, JJ, I
and, CC, I
may, MD, I
therefore, VB, I
give, VB, I
rise, NN, I
to, TO, I
more, RBR, I
standardized, JJ, I
cell, NN, I
preparations., NN, IIn, IN, I
the, DT, I
absence, NN, I
of, IN, I
isogenic, JJ, I
controls, NNS, I
for, IN, I
disease, NN, I
modeling, NN, I
applications, NNS, I
it, PRP, I
would, MD, I
therefore, RB, I
be, VB, I
more, RBR, I
appropriate, JJ, I
to, TO, I
compare, VB, I
iPSC, NN, I
from, IN, I
different, JJ, I
donors, NNS, I
rather, RB, I
than, IN, I
a, DT, I
high, JJ, I
number, NN, I
of, IN, I
different, JJ, I
clones, NNS, I
from, IN, I
the, DT, I
same, JJ, I
patient., NN, IIn, IN, I
parallel, NN, I
we, PRP, I
have, VBP, I
isolated, VBN, I
RNA, NNP, I
from, IN, I
all, DT, I
sources, NNS, I
to, TO, I
analyze, VB, I
tissue, NN, I
source, NN, I
specific, JJ, I
gene, NN, I
expression, NN, I
profile., NN, IIn, IN, I
this, DT, I
paper, NN, I
the, DT, I
generation, NN, I
and, CC, I
characterization, NN, I
of, IN, I
a, DT, I
TERT-immortalized, JJ, I
non-tumorigenic, JJ, I
human, JJ, I
bone, NN, N
marrow, NN, N
-derived, VBD, I
stromal, JJ, I
mesenchymal, JJ, I
model, NN, I
cell, NN, I
line, NN, I
is, VBZ, I
described., JJ, IInterestingly, RB, I
only, RB, I
BM-derived, JJ, I
MSPCs, NNS, I
were, VBD, I
capable, JJ, I
of, IN, I
bone, NN, I
formation, NN, I
and, CC, I
marrow, NN, I
attraction., NN, IIn, IN, I
this, DT, I
study, NN, I
we, PRP, I
have, VBP, I
analyzed, VBN, I
DNA, NNP, I
methylation, NN, I
characteristics, NNS, I
of, IN, I
human, JJ, I
mesenchymal, JJ, I
stem, NN, I
and, CC, I
progenitor, NN, I
cells, NNS, I
(MSPCs), JJ, I
form, JJ, I
different, JJ, I
tissue, NN, I
sources, NNS, I
including, VBG, I
bone, NN, N
marrow, NN, N
(BM), NNP, I
white, JJ, I
adipose, JJ, I
tissue, NN, I
(WAT, NN, I
), ), I
umbilical, JJ, I
cord, NN, I
(UC), NN, I
as, RB, I
well, RB, I
as, IN, I
dermal, JJ, I
fibroblasts, NNS, I
by, IN, I
using, VBG, I
the, DT, I
HumanMethylation450K, NNP, I
array., NN, IIn, IN, I
the, DT, I
absence, NN, I
of, IN, I
isogenic, JJ, I
controls, NNS, I
for, IN, I
disease, NN, I
modeling, NN, I
applications, NNS, I
it, PRP, I
would, MD, I
therefore, RB, I
be, VB, I
more, RBR, I
appropriate, JJ, I
to, TO, I
compare, VB, I
iPSC, NN, I
from, IN, I
different, JJ, I
donors, NNS, I
rather, RB, I
than, IN, I
a, DT, I
high, JJ, I
number, NN, I
of, IN, I
different, JJ, I
clones, NNS, I
from, IN, I
the, DT, I
same, JJ, I
patient., NN, IiPS-MSCs, JJ, I
reacquired, VBD, I
senescence-associated, JJ, I
DNAm, NNP, I
during, IN, I
culture, NN, I
expansion, NN, I
but, CC, I
they, PRP, I
remained, VBD, I
rejuvenated, VBN, I
with, IN, I
regard, NN, I
to, TO, I
age-related, JJ, I
DNAm., NNP, IIn, IN, I
this, DT, I
study, NN, I
we, PRP, I
elucidated, VBD, I
the, DT, I
DNA, NNP, I
methylome, NN, I
in, IN, I
primary, JJ, I
Acute, NNP, I
Promyelocytic, NNP, I
Leukemia, NNP, I
(APL), NNP, I
and, CC, I
the, DT, I
role, NN, I
of, IN, I
PML-RARa, NNP, I
in, IN, I
establishing, VBG, I
these, DT, I
patterns., NN, IL-MPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, NIn, IN, I
this, DT, I
study, NN, I
we, PRP, I
have, VBP, I
reprogrammed, VBN, I
mesenchymal, JJ, I
stromal, JJ, I
cells, NNS, I
(MSC), VBP, I
from, IN, I
human, JJ, I
bone, NN, N
marrow, NN, N
by, IN, I
retrovirus-mediated, JJ, I
overexpression, NN, I
of, IN, I
OCT-3/4, NNP, I
SOX2, NNP, I
c-MYC, NN, I
and, CC, I
KLF4., NNP, IMEP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, NIt, PRP, I
has, VBZ, I
been, VBN, I
suggested, VBN, I
that, IN, I
iPSC, NN, I
retain, VB, I
some, DT, I
tissue-specific, JJ, I
memory, NN, I
whereas, JJ, I
little, JJ, I
is, VBZ, I
known, VBN, I
about, IN, I
inter-individual, JJ, I
epigenetic, JJ, I
variation, NN, I
of, IN, I
iPSC, NN, I
clones., NN, IMononuclear, JJ, I
cells, NNS, I
from, IN, I
the, DT, I
bone, NN, N
marrow, NN, N
were, VBD, I
isolated, VBN, I
using, VBG, I
standard, JJ, I
density, NN, I
centrifugation, NN, I
and, CC, I
cultured, VBN, I
in, IN, I
minimum, JJ, I
essential, JJ, I
medium, NN, I
(MEM), NNP, I
Alpha, NNP, I
medium, NN, I
(cat., NN, ILymphoprep, NNP, I
extraction, NN, I
of, IN, I
leukocytes, NNS, I
was, VBD, I
performed, VBN, I
following, VBG, I
30, CD, I
min, JJ, I
no, DT, I
brake, NN, I
centrifugation., NN, IMSCs, NN, I
from, IN, I
BM, NNP, I
WAT, NNP, I
UC, NNP, I
and, CC, I
skin, NN, I
were, VBD, I
isolated, VBN, I
using, VBG, I
plastic, NN, I
adherence., NN, IMesenchymal, JJ, I
stem, NN, I
and, CC, I
progenitor, NN, I
cells, NNS, I
(MSPCs), VBP, I
from, IN, I
human, JJ, I
bone, NN, N
marrow, NN, NMSCs, NN, I
from, IN, I
three, CD, I
donors, NNS, I
were, VBD, I
infected, VBN, I
with, IN, I
pMXs, NNS, I
based, VBN, I
retroviruses, NNS, I
(Addgene, NNP, I
Cambridge, NNP, I
MA, NNP, I
USA), NNP, I
carrying, VBG, I
the, DT, I
OCT3/4, NNP, I
SOX2, NNP, I
KLF4, NNP, I
and, CC, I
c-MYC, JJ, I
genes., NN, IMPP, NNP, I
of, IN, I
normal, JJ, I
bone, NN, N
marrow, NN, NMSCs, NNP, I
were, VBD, I
subcutaneously, RB, I
implanted, VBN, I
into, IN, I
immune-compromised, JJ, I
mice, NN, I
to, TO, I
comparatively, RB, I
evaluate, VB, I
bone, NN, I
formation, NN, I
and, CC, I
subsequent, JJ, I
bone, NN, N
marrow, NN, N
attraction., NN, IMSCs, NN, I
from, IN, I
BM, NNP, I
WAT, NNP, I
UC, NNP, I
and, CC, I
skin, NN, I
were, VBD, I
isolated, VBN, I
using, VBG, I
plastic, NN, I
adherence., NN, Inormal, JJ, I
bone, NN, N
marrow, NN, N
progenitor, NN, I
cells, NNS, IMSCs, NNP, I
were, VBD, I
isolated, VBN, I
from, IN, I
bone, NN, N
marrow, NN, N
(tibia, NNP, I
plateau), NN, I
after, IN, I
written, VBN, I
consent, NN, I
using, VBG, I
guidelines, NNS, I
approved, VBN, I
by, IN, I
the, DT, I
Ethic, NNP, I
Committee, NNP, I
of, IN, I
the, DT, I
Use, NNP, I
of, IN, I
Human, NNP, I
Subjects, NNP, I
at, IN, I
the, DT, I
University, NNP, I
of, IN, I
Aachen, NNP, I
(permit, NNP, I
number:, IN, I
EK128/09)., NNP, IOverall, JJ, I
DNA-methylation, NNP, I
patterns, NNS, I
of, IN, I
iP-MSC, JJ, I
and, CC, I
ESC, NNP, I
were, VBD, I
similar, JJ, I
whereas, NNS, I
some, DT, I
CpG, NNP, I
sites, NNS, I
revealed, VBD, I
highly, RB, I
significant, JJ, I
differences, NNS, I
which, WDT, I
were, VBD, I
not, RB, I
related, VBN, I
to, TO, I
parental, JJ, I
MSC., NNP, INon-adherent, JJ, I
cells, NNS, I
were, VBD, I
removed, VBN, I
after, IN, I
approximately, RB, I
24, CD, I
h, NNS, I
by, IN, I
replacement, NN, I
of, IN, I
the, DT, I
medium., NN, IPatient, NN, I
and, CC, I
donor, NN, I
samples, NNS, I
were, VBD, I
obtained, VBN, I
either, RB, I
from, IN, I
blood, NN, I
or, CC, I
bone, NN, N
marrow, NN, N
., ., INormal, NNP, I
human, JJ, I
bone, NN, N
marrow, NN, N
cells, NNS, IPrimary, JJ, I
hMSCs, NN, I
were, VBD, I
obtained, VBN, I
from, IN, I
the, DT, I
hip, NN, I
of, IN, I
a, DT, I
healthy, JJ, I
donor, NN, I
after, IN, I
informed, VBN, I
consent., NN, IOverall, JJ, I
iPS-MSCs, NN, I
and, CC, I
MSCs, NNP, I
are, VBP, I
similar, JJ, I
in, IN, I
function, NN, I
but, CC, I
differ, NN, I
in, IN, I
their, PRP$, I
epigenetic, JJ, I
makeup., NN, IReprogramming, VBG, I
of, IN, I
somatic, JJ, I
cells, NNS, I
into, IN, I
induced, JJ, I
pluripotent, JJ, I
stem, NN, I
cells, NNS, I
(iPSC), NNP, I
is, VBZ, I
an, DT, I
epigenetic, JJ, I
phenomenon., NN, Iprimary, JJ, I
cells, NNS, I
isolated, VBN, I
from, IN, I
patient's, JJ, I
blood, NN, I
or, CC, I
bone, NN, N
marrow, NN, Nsample, NN, I
origin:, MD, I
Human, NNP, I
bone, NN, N
marrow, NN, N
-derived, VBD, I
mesenchymal, JJ, I
stromal, NN, I
cell, NN, IReprogramming, VBG, I
of, IN, I
somatic, JJ, I
cells, NNS, I
into, IN, I
induced, JJ, I
pluripotent, JJ, I
stem, NN, I
cells, NNS, I
(iPSC), NNP, I
is, VBZ, I
an, DT, I
epigenetic, JJ, I
phenomenon., NN, Isample, NN, I
type:, NN, I
Remission, NNP, I
bone, NN, N
marrow, NN, NRUNX2, NNP, I
target, NN, I
genes, NNS, I
were, VBD, I
associated, VBN, I
with, IN, I
cellular, JJ, I
growth, NN, I
movement, NN, I
apoptosis, NN, I
and, CC, I
PDGF, NNP, I
BB, NNP, I
and, CC, I
p53, NN, I
signaling., NN, ISorted, VBN, I
normal, JJ, I
bone, NN, N
marrow, NN, N
cells, NNS, I
from, IN, I
healthy, JJ, I
volunteers, NNS, I
at, IN, I
Washington, NNP, I
University, NNP, ISamples, NNS, I
included, VBD, I
20, CD, I
leukemia, NN, I
stem, NN, I
cells, NNS, I
24, CD, I
blast, NN, I
cells, NNS, I
and, CC, I
30, CD, I
normal, JJ, I
hematopoietic, JJ, I
stem, NN, I
and, CC, I
progenitor, NN, I
cells, NNS, I
(6, JJ, I
different, JJ, I
types, NNS, I
from, IN, I
5, CD, I
normal, JJ, I
bone, NN, N
marrow, NN, N
s)., NN, IStarting, VBG, I
material, NN, I
and, CC, I
culture, NN, I
expansion, NN, I
affect, NN, I
cell, NN, I
preparations, NNS, I
and, CC, I
render, VB, I
comparison, NN, I
between, IN, I
studies, NNS, I
difficult., VBP, ISelf-renewal, NNP, I
and, CC, I
multipotent, JJ, I
differentiation, NN, I
capacity, NN, I
are, VBP, I
key, JJ, I
elements, NNS, I
in, IN, I
the, DT, I
increasing, VBG, I
interest, NN, I
of, IN, I
this, DT, I
cell, NN, I
type., NN, ISubsequently, RB, I
we, PRP, I
searched, VBD, I
for, IN, I
CpG, NNP, I
sites, NNS, I
with, IN, I
donor-specific, JJ, I
variation, NN, I
in, IN, I
MSC, NNP, I
preparations., NN, IStandardization, NN, I
of, IN, I
mesenchymal, JJ, I
stromal, JJ, I
cells, NNS, I
(MSCs), VBP, I
remains, VBZ, I
a, DT, I
major, JJ, I
obstacle, NN, I
in, IN, I
regenerative, JJ, I
medicine., NN, ISUZ12, NNP, I
and, CC, I
REST, NNP, I
binding, NN, I
sites, NNS, I
identified, VBN, I
in, IN, I
embryonic, JJ, I
stem, NN, I
cells, NNS, I
were, VBD, I
however, RB, I
preferentially, RB, I
DNA, NNP, I
hypermethylated, VBD, I
in, IN, I
APL., NNP, ISubsequently, RB, I
the, DT, I
adherent, NN, I
cells, NNS, I
were, VBD, I
allowed, VBN, I
to, TO, I
expand, VB, I
until, IN, I
70%, CD, I
confluence, NN, I
(5–6, NNP, I
days), NN, I
before, IN, I
they, PRP, I
were, VBD, I
harvested, VBN, I
and, CC, I
further, RBR, I
expanded., NN, IThe, DT, I
gene, NN, I
expression, NN, I
profiles, NNS, I
of, IN, I
immortalized, JJ, I
and, CC, I
primary, JJ, I
hMSCs, NN, I
were, VBD, I
also, RB, I
similar, JJ, I
whereas, IN, I
the, DT, I
corresponding, JJ, I
methylation, NN, I
profiles, NNS, I
were, VBD, I
more, JJR, I
diverse., NNS, ISurprisingly, RB, I
RUNX2, NNP, I
was, VBD, I
found, VBN, I
to, TO, I
bind, VB, I
both, DT, I
at, IN, I
the, DT, I
5’, CD, I
and, CC, I
3’, CD, I
ends, NNS, I
of, IN, I
genes, NNS, I
and, CC, I
also, RB, I
at, IN, I
distal, JJ, I
regulatory, JJ, I
elements, NNS, I
and, CC, I
was, VBD, I
co-localized, VBN, I
with, IN, I
activating, VBG, I
histone, NN, I
modifications, NNS, I
at, IN, I
approximately, RB, I
half, NN, I
of, IN, I
bound, NN, I
sites., NN, IThe, DT, I
origin, NN, I
of, IN, I
aberrant, JJ, I
DNA, NNP, I
methylation, NN, I
in, IN, I
cancer, NN, I
remains, VBZ, I
largely, RB, I
unknown., JJ, IThe, DT, I
cell, NN, I
line, NN, I
had, VBD, I
a, DT, I
normal, JJ, I
karyotype, NN, I
and, CC, I
high-resolution, NN, I
array, NN, I
comparative, JJ, I
genomic, JJ, I
hybridization, NN, I
confirmed, VBD, I
that, IN, I
the, DT, I
cells, NNS, I
in, IN, I
general, JJ, I
had, VBD, I
normal, JJ, I
copy, NN, I
number., NN, IThe, DT, I
resulting, VBG, I
cell, NN, I
line, NN, I
iMSC#3, NN, I
maintained, VBD, I
capacity, NN, I
to, TO, I
differentiate, VB, I
into, IN, I
osteoblasts, NNS, I
and, CC, I
adipocytes, NNS, I
and, CC, I
growth, NN, I
characteristics, NNS, I
comparable, JJ, I
to, TO, I
primary, JJ, I
hMSCs, NN, I
into, IN, I
after, IN, I
long-term, JJ, I
culturing, NN, I
(155, JJ, I
population, NN, I
doublings)., NN, IThe, DT, I
Illumina, NNP, I
Infinium, NNP, I
450k, CD, I
Human, NNP, I
DNA, NNP, I
methylation, NN, I
Beadchip, NNP, I
was, VBD, I
used, VBN, I
to, TO, I
obtain, VB, I
DNA, NNP, I
methylation, NN, I
profiles, NNS, I
across, IN, I
approximately, RB, I
450000, CD, I
CpGs, NNP, I
in, IN, I
the, DT, I
samples., NN, IThese, DT, I
features, NNS, I
correlated, VBD, I
with, IN, I
unique, JJ, I
epigenetic, JJ, I
characteristics, NNS, I
potentially, RB, I
enabling, VBG, I
BM-derived, NNP, I
cells, NNS, I
to, TO, I
undergo, VB, I
endochondral, JJ, I
ossification., NN, IThe, DT, I
predictions, NNS, I
were, VBD, I
confirmed, VBN, I
by, IN, I
siRNA, JJ, I
knockdown, NN, I
of, IN, I
the, DT, I
transcription, NN, I
factors, NNS, I
which, WDT, I
lead, VBP, I
to, TO, I
inhibition, NN, I
of, IN, I
differentiation., NN, IThese, DT, I
results, NNS, I
suggest, VBP, I
that, IN, I
aberrant, JJ, I
DNA, NNP, I
methylation, NN, I
is, VBZ, I
associated, VBN, I
with, IN, I
leukemia, NN, I
phenotype, NN, I
but, CC, I
not, RB, I
required, VBN, I
for, IN, I
PML-RARa-mediated, JJ, I
initiation, NN, I
of, IN, I
leukemogenesis., NN, IThese, DT, I
“epigenetic, JJ, I
fingerprints”, NNS, I
were, VBD, I
highly, RB, I
enriched, VBN, I
in, IN, I
non-promoter, JJ, I
regions, NNS, I
and, CC, I
outside, NN, I
of, IN, I
CpG, NNP, I
islands, NNS, I
–, VBP, I
and, CC, I
they, PRP, I
were, VBD, I
maintained, VBN, I
upon, IN, I
reprogramming, VBG, I
into, IN, I
iP-MSC., JJ, IThe, DT, I
study, NN, I
investigated, VBD, I
the, DT, I
changes, NNS, I
in, IN, I
DNA-methylation, NNP, I
and, CC, I
gene, NN, I
expression, NN, I
during, IN, I
granulopoiesis., NN, IThese, DT, I
iPS-MSCs, JJ, I
revealed, VBD, I
similar, JJ, I
morphology, NN, I
immunophenotype, NN, I
in, IN, I
vitro, JJ, I
differentiation, NN, I
potential, NN, I
and, CC, I
gene, NN, I
expression, NN, I
profiles, NNS, I
as, IN, I
primary, JJ, I
MSCs., NNP, IThis, DT, I
is, VBZ, I
to, TO, I
our, PRP$, I
knowledge, NN, I
the, DT, I
first, JJ, I
genome-wide, JJ, I
description, NN, I
of, IN, I
RUNX2, NNP, I
targets, NNS, I
in, IN, I
bone, NN, I
biology., NN, IThe, DT, I
study, NN, I
investigated, VBD, I
the, DT, I
abberrent, NN, I
DNA, NNP, I
methylation, NN, I
in, IN, I
correlation, NN, I
with, IN, I
gene, NN, I
expression, NN, I
in, IN, I
cytogenetic, JJ, I
normal, JJ, I
acute, NN, I
myeloid, NN, I
leukemia., NN, Itisse, NN, I
source, NN, I
for, IN, I
mscs:, NN, I
bone, NN, N
marrow, NN, N
(BM), NN, IThe, DT, I
trabecular, JJ, I
bone, NN, I
pieces, NNS, I
were, VBD, I
obtained, VBN, I
from, IN, I
the, DT, I
central, JJ, I
part, NN, I
of, IN, I
the, DT, I
femoral, JJ, I
head, NN, I
of, IN, I
Spanish, JJ, I
(Caucasian), NN, I
patients, NNS, I
with, IN, I
hip, NN, I
fractures, NNS, I
(due, VBP, I
to, TO, I
osteoporosis), VB, I
or, CC, I
subjects, NNS, I
with, IN, I
osteoarthritis., NN, Itissue:, JJ, I
fetal, JJ, I
bone, NN, N
marrow, NN, Ntisse, NN, I
source, NN, I
for, IN, I
mscs:, NN, I
bone, NN, N
marrow, NN, N
(BM), NN, ITo, TO, I
gain, VB, I
mechanistic, JJ, I
insights, NNS, I
explaining, VBG, I
this, DT, I
differences, VBZ, I
we, PRP, I
analyzed, VBD, I
gene, NN, I
expression, NN, I
characteristics, NNS, I
of, IN, I
MSC, NNP, I
from, IN, I
all, DT, I
four, CD, I
tissue, NN, I
sources, NNS, I
using, VBG, I
Affymetrix, NNP, I
Genechip, NNP, I
Human, NNP, I
Gene, NNP, I
2.0, CD, I
ST, NNP, I
Array., NNP, Itissue:, NN, I
bone, NN, N
marrow, NN, N
/, NNP, I
peripheral, JJ, I
blood, NN, ITo, TO, I
this, DT, I
end, NN, I
CMP, NNP, I
GMP, NNP, I
PMC, NNP, I
and, CC, I
PMN, NNP, I
cell, VBP, I
populations, NNS, I
were, VBD, I
isolated, VBN, I
by, IN, I
FACS, NNP, I
from, IN, I
bone, NN, N
marrow, NN, N
from, IN, I
healthy, JJ, I
donors, NNS, I
and, CC, I
analysed, VBN, I
by, IN, I
CAGE, NNP, I
as, RB, I
well, RB, I
as, IN, I
expression, NN, I
and, CC, I
DNA, NNP, I
microarrays., NN, ITo, TO, I
exclude, VB, I
contamination, NN, I
of, IN, I
feeder, NN, I
layer, NN, I
cells, NNS, I
iPSCs, VBP, I
were, VBD, I
adjusted, VBN, I
to, TO, I
a, DT, I
feeder-free, JJ, I
system, NN, I
on, IN, I
matrigel, NN, I
(BD, NN, I
Biosciences, NNP, I
San, NNP, I
Jose, NNP, I
CA, NNP, I
USA), NNP, I
in, IN, I
mTeSR™1, JJ, I
medium, NN, I
(Stemcell, NNP, I
Technologies, NNPS, I
Vancouver, NNP, I
BC, NNP, I
Canada), NNP, I
for, IN, I
at, IN, I
least, JJS, I
three, CD, I
passages., NN, IUnexpectedly, RB, I
PML-RARa, NNP, I
binding, VBG, I
sites, NNS, I
were, VBD, I
also, RB, I
protected, VBN, I
from, IN, I
aberrant, JJ, I
DNA, NNP, I
methylation, NN, I
in, IN, I
APL., NNP, ITo, TO, I
gain, VB, I
mechanistic, JJ, I
insights, NNS, I
explaining, VBG, I
this, DT, I
differences, VBZ, I
we, PRP, I
analyzed, VBD, I
gene, NN, I
expression, NN, I
characteristics, NNS, I
of, IN, I
MSC, NNP, I
from, IN, I
all, DT, I
four, CD, I
tissue, NN, I
sources, NNS, I
using, VBG, I
Affymetrix, NNP, I
Genechip, NNP, I
Human, NNP, I
Gene, NNP, I
2.0, CD, I
ST, NNP, I
Array., NNP, IWe, PRP, I
here, RB, I
describe, VBP, I
the, DT, I
pattern, NN, I
of, IN, I
gene, NN, I
expression, NN, I
histone, NN, I
modification, NN, I
and, CC, I
DNA, NNP, I
binding, NN, I
of, IN, I
the, DT, I
bone, NN, I
master, NN, I
regulator, NN, I
RUNX2, NNP, I
during, IN, I
osteogenic, JJ, I
differentiation, NN, I
of, IN, I
an, DT, I
immortalized, JJ, I
human, JJ, I
bone, NN, N
marrow, NN, N
-derived, VBD, I
MSC, NNP, I
cell, NN, I
line., NN, ITranscription, NNP, I
factor, NN, I
binding, VBG, I
sites, NNS, I
e.g., VBP, IWhere, WRB, I
available, JJ, I
purification, NN, I
was, VBD, I
performed, VBN, I
using, VBG, I
MACS, NNP, I
columns, NN, I
following, VBG, I
anti-CD34, JJ, I
bead, JJ, I
conjugation, NN, I
to, TO, I
samples, VB, I
(anti-CD14, NNP, I
for, IN, I
CD14, NNP, I
samles)., NN, IWe, PRP, I
examined, VBD, I
DNA, NNP, I
methylation, NN, I
and, CC, I
RNA, NNP, I
expression, NN, I
status, NN, I
during, IN, I
early, JJ, I
B-cell, NNP, I
development, NN, I
by, IN, I
sorting, VBG, I
multiple, JJ, I
replicates, NNS, I
of, IN, I
four, CD, I
separate, JJ, I
stages, NNS, I
of, IN, I
pre-B, JJ, I
cells, NNS, I
derived, VBN, I
from, IN, I
normal, JJ, I
human, JJ, I
fetal, JJ, I
bone, NN, N
marrow, NN, N
and, CC, I
applied, VBD, I
high-dimension, NN, I
DNA, NNP, I
methylation, NN, I
scanning, NN, I
and, CC, I
expression, NN, I
arrays., NN, IWe, PRP, I
reprogrammed, VBD, I
bone, NN, N
marrow, NN, N
MSCs, NNP, I
into, IN, I
iPSCs, NN, I
which, WDT, I
were, VBD, I
subsequently, RB, I
re-differentiated, JJ, I
towards, NNS, I
MSCs., NNP, I